Hassan Jomaa

Author PubWeight™ 70.90‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Microbial isoprenoid biosynthesis and human gammadelta T cell activation. FEBS Lett 2003 2.30
2 Fosmidomycin for malaria. Lancet 2002 2.03
3 The interplay between classical and alternative isoprenoid biosynthesis controls gammadelta T cell bioactivity of Listeria monocytogenes. FEBS Lett 2004 1.93
4 New antimalarial drugs. Angew Chem Int Ed Engl 2003 1.68
5 In vitro and in vivo synergy of fosmidomycin, a novel antimalarial drug, with clindamycin. Antimicrob Agents Chemother 2002 1.65
6 RlmN and Cfr are radical SAM enzymes involved in methylation of ribosomal RNA. J Am Chem Soc 2010 1.60
7 Structure of (E)-4-hydroxy-3-methyl-but-2-enyl diphosphate reductase, the terminal enzyme of the non-mevalonate pathway. J Am Chem Soc 2008 1.57
8 LytB protein catalyzes the terminal step of the 2-C-methyl-D-erythritol-4-phosphate pathway of isoprenoid biosynthesis. FEBS Lett 2002 1.55
9 Fosmidomycin, a novel chemotherapeutic agent for malaria. Antimicrob Agents Chemother 2003 1.46
10 Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy. J Immunol 2007 1.42
11 Fosmidomycin for the treatment of malaria. Parasitol Res 2002 1.40
12 Fosmidomycin plus clindamycin for treatment of pediatric patients aged 1 to 14 years with Plasmodium falciparum malaria. Antimicrob Agents Chemother 2006 1.35
13 Fosmidomycin-clindamycin for Plasmodium falciparum Infections in African children. J Infect Dis 2004 1.35
14 Fosmidomycin-clindamycin for the treatment of Plasmodium falciparum malaria. J Infect Dis 2004 1.34
15 Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate-driven antimicrobial and cytotoxic responses of pulmonary and systemic Vgamma2Vdelta2 T cells in macaques. J Immunol 2007 1.32
16 The methylerythritol phosphate pathway is functionally active in all intraerythrocytic stages of Plasmodium falciparum. J Biol Chem 2004 1.31
17 Functional characterization of GcpE, an essential enzyme of the non-mevalonate pathway of isoprenoid biosynthesis. FEBS Lett 2002 1.17
18 Sex-specific phenotypical and functional differences in peripheral human Vgamma9/Vdelta2 T cells. J Leukoc Biol 2006 1.08
19 Differentiation of human gamma-delta T cells towards distinct memory phenotypes. Cell Immunol 2002 1.07
20 Antigen-specific Vgamma2Vdelta2 T effector cells confer homeostatic protection against pneumonic plaque lesions. Proc Natl Acad Sci U S A 2009 1.05
21 Crystal structure of 1-deoxy-D-xylulose-5-phosphate reductoisomerase, a crucial enzyme in the non-mevalonate pathway of isoprenoid biosynthesis. J Biol Chem 2001 1.05
22 Fosmidomycin uptake into Plasmodium and Babesia-infected erythrocytes is facilitated by parasite-induced new permeability pathways. PLoS One 2011 1.04
23 Double ester prodrugs of FR900098 display enhanced in-vitro antimalarial activity. Arch Pharm (Weinheim) 2007 1.03
24 Isoprenoid biosynthesis of the apicoplast as drug target. Curr Drug Targets 2007 1.03
25 Synthesis of alpha-substituted fosmidomycin analogues as highly potent Plasmodium falciparum growth inhibitors. Bioorg Med Chem Lett 2006 1.03
26 Phosphoantigen/IL2 expansion and differentiation of Vγ2Vδ2 T cells increase resistance to tuberculosis in nonhuman primates. PLoS Pathog 2013 1.02
27 The nonmevalonate pathway of isoprenoid biosynthesis in Mycobacterium tuberculosis is essential and transcriptionally regulated by Dxs. J Bacteriol 2010 1.02
28 Human Vgamma9/Vdelta2 effector memory T cells express the killer cell lectin-like receptor G1 (KLRG1). J Leukoc Biol 2004 1.02
29 Reconstitution of an apicoplast-localised electron transfer pathway involved in the isoprenoid biosynthesis of Plasmodium falciparum. FEBS Lett 2005 1.00
30 Synthesis of beta- and gamma-oxa isosteres of fosmidomycin and FR900098 as antimalarial candidates. Bioorg Med Chem 2007 1.00
31 Gammadelta T cell immune manipulation during chronic phase of simian-human immunodeficiency virus infection [corrected] confers immunological benefits. J Immunol 2009 0.99
32 Short-course regimens of artesunate-fosmidomycin in treatment of uncomplicated Plasmodium falciparum malaria. Antimicrob Agents Chemother 2005 0.99
33 Farnesyltransferase inhibitors inhibit the growth of malaria parasites in vitro and in vivo. Angew Chem Int Ed Engl 2004 0.98
34 Accumulation of a potent gammadelta T-cell stimulator after deletion of the lytB gene in Escherichia coli. Immunology 2002 0.98
35 Crystallographic structures of two bisphosphonate:1-deoxyxylulose-5-phosphate reductoisomerase complexes. J Am Chem Soc 2004 0.97
36 Possible direct involvement of the active-site [4Fe-4S] cluster of the GcpE enzyme from Thermus thermophilus in the conversion of MEcPP. FEBS Lett 2006 0.97
37 Novel deoxyxylulosephosphate-reductoisomerase inhibitors: fosmidomycin derivatives with spacious acyl residues. Arch Pharm (Weinheim) 2007 0.96
38 Structure-activity relationships of novel anti-malarial agents. Part 3: N-(4-acylamino-3-benzoylphenyl)-4-propoxycinnamic acid amides. Bioorg Med Chem Lett 2002 0.95
39 Acyloxyalkyl ester prodrugs of FR900098 with improved in vivo anti-malarial activity. Bioorg Med Chem Lett 2003 0.94
40 Paramagnetic intermediates of (E)-4-hydroxy-3-methylbut-2-enyl diphosphate synthase (GcpE/IspG) under steady-state and pre-steady-state conditions. J Am Chem Soc 2010 0.94
41 Structure of the E-1-hydroxy-2-methyl-but-2-enyl-4-diphosphate synthase (GcpE) from Thermus thermophilus. FEBS Lett 2010 0.94
42 Delayed parasite elimination in human infections treated with clindamycin parallels 'delayed death' of Plasmodium falciparum in vitro. Int J Parasitol 2006 0.93
43 Replacing the pyrophosphate group of HMB-PP by a diphosphonate function abrogates Its potential to activate human gammadelta T cells but does not lead to competitive antagonism. Bioorg Med Chem Lett 2003 0.93
44 Towards new antimalarial drugs: synthesis of non-hydrolyzable phosphate mimics as feed for a predictive QSAR study on 1-deoxy-D-xylulose-5-phosphate reductoisomerase inhibitors. Chem Biodivers 2008 0.91
45 Synthesis of analogues of (E)-1-hydroxy-2-methylbut-2-enyl 4-diphosphate, an isoprenoid precursor and human gamma delta T cell activator. J Org Chem 2008 0.90
46 Mycoplasma penetrans is capable of activating V gamma 9/V delta 2 T cells while other human pathogenic mycoplasmas fail to do so. Infect Immun 2004 0.87
47 Alkoxycarbonyloxyethyl ester prodrugs of FR900098 with improved in vivo antimalarial activity. Arch Pharm (Weinheim) 2005 0.86
48 Divergent strategy for the synthesis of alpha-aryl-substituted fosmidomycin analogues. J Org Chem 2007 0.86
49 Synthesis and evaluation of alpha,beta-unsaturated alpha-aryl-substituted fosmidomycin analogues as DXR inhibitors. Bioorg Med Chem Lett 2007 0.86
50 Antimalarial activity of n(6)-substituted adenosine derivatives (part 2). J Comb Chem 2002 0.85
51 Analysis of the isoprenoid biosynthesis pathways in Listeria monocytogenes reveals a role for the alternative 2-C-methyl-D-erythritol 4-phosphate pathway in murine infection. Infect Immun 2008 0.85
52 Synthesis and biological evaluation of cyclopropyl analogues of fosmidomycin as potent Plasmodium falciparum growth inhibitors. J Med Chem 2006 0.82
53 Studies addressing the importance of charge in the binding of fosmidomycin-like molecules to deoxyxylulosephosphate reductoisomerase. ChemMedChem 2008 0.82
54 Synthesis of the antimalarial drug FR900098 utilizing the nitroso-ene reaction. Org Lett 2007 0.81
55 Structure of the (E)-4-hydroxy-3-methyl-but-2-enyl-diphosphate reductase from Plasmodium falciparum. FEBS Lett 2013 0.81
56 Structure of the GcpE (IspG)-MEcPP complex from Thermus thermophilus. FEBS Lett 2012 0.81
57 Anti-malarial activity of N(6)-substituted adenosine derivatives. Part I. Bioorg Med Chem 2002 0.81
58 Structure-activity relationships of novel anti-malarial agents. Part 6: N-(4-arylpropionylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem Lett 2003 0.79
59 Non-thiol farnesyltransferase inhibitors: N-(4-aminoacylamino-3-benzoylphenyl)-3-[5-(4-nitrophenyl)-2 furyl]acrylic acid amides and their antimalarial activity. Eur J Med Chem 2005 0.79
60 Integrated immune responses to infection - cross-talk between human gammadelta T cells and dendritic cells. Immunology 2004 0.79
61 Primary MHC-class II(+) cells are necessary to promote resting Vδ2 cell expansion in response to (E)-4-hydroxy-3-methyl-but-2-enyl-pyrophosphate and isopentenyl pyrophosphate. J Immunol 2012 0.79
62 Determination of fosmidomycin in human serum and urine by capillary electrophoresis. J Chromatogr B Analyt Technol Biomed Life Sci 2004 0.78
63 Interferon-beta therapy reduces CD4+ and CD8+ T-cell reactivity in multiple sclerosis. Immunology 2006 0.78
64 Development of benzophenone-based farnesyltransferase inhibitors as novel antimalarials. ChemMedChem 2008 0.77
65 Antimalarial activity of N(6)-substituted adenosine derivatives. Part 3. Bioorg Med Chem 2004 0.77
66 A genetic basis for human gammadelta T-cell reactivity towards microbial pathogens. Trends Immunol 2003 0.76
67 Structure-activity relationships of novel anti-malarial agents: part 5. N-(4-acylamino-3-benzoylphenyl)-[5-(4-nitrophenyl)-2-furyl]acrylic acid amides. Bioorg Med Chem Lett 2003 0.75
68 Structure-activity relationships of novel anti-malarial agents. Part 4: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides. Bioorg Med Chem Lett 2002 0.75
69 Structure-activity relationships of novel anti-malarial agents. Part 7: N-(3-benzoyl-4-tolylacetylaminophenyl)-3-(5-aryl-2-furyl)acrylic acid amides with polar moieties. Bioorg Med Chem Lett 2003 0.75
70 NMR studies of DOXP reductoisomerase and its inhibitor complex. Chembiochem 2011 0.75